Discussion on the current market price of Venetoclax/Venetoclax

Venetoclax/Venetoclax, as a highly effective and selective B-cell lymphoma 2 (BCL-2) inhibitor, has been widely recognized and used to treat a variety of hematological malignancies, such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL). Its anti-apoptotic mechanism is mainly achieved by inhibiting the BCL-2 protein family. These proteins are up-regulated in cancer cells and combine with pro-apoptotic factors, thereby helping cancer cells escape the natural apoptotic process and even develop drug resistance. In certain types of cells, overexpression of BCL-2 becomes key to preventing apoptosis, while venetoclax can effectively promote apoptosis induced by other drugs such as PIs.

Today, Venacla’s original drugs have been launched in China, providing patients with a variety of specifications to meet different needs. In terms of price, depending on the specifications, each box of medicines is priced between 1,000 yuan and 4,000 yuan. What is gratifying is that this drug has been included in the Class B medical insurance catalog. However, the scope of medical insurance reimbursement is limited to patients diagnosed with adult acute myeloid leukemia.

For patients who are considering purchasing drugs from overseas, the price of the Turkish version of the original drug is relatively high, with the price of each box reaching more than 10,000 yuan, which contains112 100mg tablets. In addition, there are also generic drugs of Venetoclax on the market, and the main ingredients of these drugs are very close to the original drugs. For example, a box of generic drugs produced by a pharmaceutical factory in Laos contains 120 100mg tablets, and the price is only about 2,000 yuan. The prices of these medicines may change due to exchange rate fluctuations.